226067-37-4

Basic information

• Product Name: Boc-N-Me-D-Thr(Bzl)-OH
• Synonyms: Boc-N-Me-D-Thr(Bzl)-OH
• CAS NO: 226067-37-4
• Molecular Formula: C₁₇H₂₅NO₅
• Molecular Weight: 323.38
• Product Categories: amino acids
• Mol File: 226067-37-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Boc-N-Me-D-Thr(Bzl)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-N-Me-D-Thr(Bzl)-OH(226067-37-4)
• EPA Substance Registry System: Boc-N-Me-D-Thr(Bzl)-OH(226067-37-4)

Safety Data

• Hazardous Substances Data: 226067-37-4(Hazardous Substances Data)

Upstream product

• 69355-99-3 Boc-O-benzyl-D-threonine 
• 74-88-4 methyl iodide 

Downstream Products

• 1439366-92-3 5-phenylpentyl N-methyl-N-[(2S,3R)-2-methyl-4-oxo-oxetan-3-yl]-carbamate 
• 1439367-96-0 (2R,3S)-3-hydroxy-2-[methyl-(5-phenylpentoxycarbonyl)-amino]-butanoic acid 
• 1439367-95-9 [(1R,2S)-1-carboxy-2-hydroxy-propyl]-methyl-ammonium toluene-4-sulfonate 
• 170872-87-4 (2R,3S)-2-[tert-butoxycarbonyl-(methyl)-amino]-3-hydroxy-butanoic acid 
• 474085-54-6 (2R,3S)-3-Benzyloxy-2-(tert-butoxycarbonyl-methyl-amino)-butyric acid benzyl ester 

Relevant articles and documents

Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)

The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA)

The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.